PMID- 38089401
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231213
IS  - 2770-9183 (Electronic)
IS  - 2770-9191 (Print)
IS  - 2770-9183 (Linking)
VI  - 2
IP  - 3
DP  - 2023 Jun
TI  - A real-world study of immune checkpoint inhibitors in advanced triple-negative 
      breast cancer.
PG  - 172-180
LID - 10.1002/cai2.70 [doi]
AB  - BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive type of 
      breast cancer. Immune checkpoint inhibitors (ICIs) have been widely used to treat 
      various tumors and have changed the landscape of tumor management, but the data 
      from real-world studies of ICIs for TNBC treatment remain limited. The aim of 
      this study was to evaluate the efficacy of ICIs in the treatment of patients with 
      advanced TNBC in a real-world setting and to explore possible correlates. 
      METHODS: The clinical data of advanced TNBC patients who received ICI treatment 
      in the Chinese People's Liberation Army (PLA) General Hospital were collected. 
      Treatment responses, outcomes and adverse events (AEs) were assessed. RESULTS: 
      Eighty-one patients were included in the study. The confirmed objective response 
      rate (ORR) was 32.1%, and the disease control rate (DCR) was 64.2%. The median 
      progression-free survival (PFS) was 4.2 months, and the median overall survival 
      (OS) was 11.0 months. PFS and OS were longer in patients who achieved clinical 
      benefit from ICIs and shorter in patients who received later-line ICIs and higher 
      levels of inflammation; specifically, patients with higher TILs had longer PFS. 
      Overall AEs were tolerable. CONCLUSIONS: ICIs are effective in the treatment of 
      advanced TNBC, and the adverse reactions are tolerable. A panel of biomarkers 
      including LDH, ALP, and bNLR were identified to predict the efficacies of ICIs in 
      TNBC treatment.
CI  - (c) 2023 The Authors. Cancer Innovation published by John Wiley & Sons Ltd. on 
      behalf of Tsinghua University Press.
FAU - Zhang, Zheng
AU  - Zhang Z
AUID- ORCID: 0000-0003-4335-8056
AD  - Medical School of Chinese PLA Beijing China.
FAU - Zhang, Yadi
AU  - Zhang Y
AD  - Nankai University School of Medicine Tianjin China.
FAU - Liu, Chuanling
AU  - Liu C
AD  - Medical School of Chinese PLA Beijing China.
FAU - Shao, Jiakang
AU  - Shao J
AD  - Medical School of Chinese PLA Beijing China.
FAU - Chen, Yimeng
AU  - Chen Y
AD  - Department of Medical Oncology Xi'an Jiaotong University Xi'an Shaanxi China.
FAU - Zhu, Yimin
AU  - Zhu Y
AD  - Department of Medical Oncology, Fifth Medical Center General Hospital of the 
      Chinese People's Liberation Army Beijing China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Medical Oncology, First Medical Center General Hospital of the 
      Chinese People's Liberation Army Beijing China.
FAU - Qin, Boyu
AU  - Qin B
AD  - Department of Medical Oncology, Fifth Medical Center General Hospital of the 
      Chinese People's Liberation Army Beijing China.
FAU - Kong, Ziqing
AU  - Kong Z
AD  - Medical School of Chinese PLA Beijing China.
FAU - Wang, Xixi
AU  - Wang X
AD  - Nankai University School of Medicine Tianjin China.
FAU - Wang, Yutong
AU  - Wang Y
AD  - Medical School of Chinese PLA Beijing China.
FAU - Huang, Deqin
AU  - Huang D
AD  - Medical School of Chinese PLA Beijing China.
FAU - Liu, Liqun
AU  - Liu L
AD  - Medical School of Chinese PLA Beijing China.
FAU - Zhou, Yuxin
AU  - Zhou Y
AD  - Medical School of Chinese PLA Beijing China.
FAU - Tao, Ran
AU  - Tao R
AD  - Department of Medical Oncology, First Medical Center General Hospital of the 
      Chinese People's Liberation Army Beijing China.
FAU - Yang, Zengjie
AU  - Yang Z
AD  - Cancer Biology Program Fox Chase Cancer Center Philadelphia Pennsylvania USA.
FAU - Liu, Mei
AU  - Liu M
AD  - Department of Pathology, First Medical Center General Hospital of the Chinese 
      People's Liberation Army Beijing China.
FAU - Zhao, Weihong
AU  - Zhao W
AUID- ORCID: 0000-0003-0223-2182
AD  - Department of Medical Oncology, First Medical Center General Hospital of the 
      Chinese People's Liberation Army Beijing China.
LA  - eng
PT  - Journal Article
DEP - 20230423
PL  - England
TA  - Cancer Innov
JT  - Cancer innovation
JID - 9918713888606676
PMC - PMC10686160
OTO - NOTNLM
OT  - ICIs
OT  - TNBC
OT  - biomarkers
OT  - efficacy evaluation
OT  - prognosis
OT  - safety
COIS- The authors declare no conflict of interest.
EDAT- 2023/12/13 18:42
MHDA- 2023/12/13 18:43
PMCR- 2023/04/23
CRDT- 2023/12/13 12:50
PHST- 2023/02/28 00:00 [received]
PHST- 2023/03/08 00:00 [revised]
PHST- 2023/03/16 00:00 [accepted]
PHST- 2023/12/13 18:43 [medline]
PHST- 2023/12/13 18:42 [pubmed]
PHST- 2023/12/13 12:50 [entrez]
PHST- 2023/04/23 00:00 [pmc-release]
AID - CAI270 [pii]
AID - 10.1002/cai2.70 [doi]
PST - epublish
SO  - Cancer Innov. 2023 Apr 23;2(3):172-180. doi: 10.1002/cai2.70. eCollection 2023 
      Jun.